mRNA regulations
mRNA Regulatory Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA32Sep 15, 2026
cell therapy
Survey of Cell Therapy Formats
Sophie Lutter, Ph.D.
Lab Thread
NI-8-26-MA48Sep 15, 2026
cell therapy
The Expanding Role of Living Cell Treatments
Sophie Lutter, Ph.D.
Lab Thread
NI-8-26-MA47Sep 15, 2026
history cell therapy
History of Cell Therapies
Sophie Lutter, Ph.D.
Lab Thread
NI-8-26-MA49Sep 15, 2026
analytics / biologic
Analytical Basics for Biologics
April Stanley, MS MBA
Nice Insight
NI-8-26-MA37Sep 15, 2026
sterile
Challenges and Innovation in Sterile Manufacturing
April Stanley, MS MBA
Nice Insight
NI-8-26-MA46Sep 15, 2026
Sterile market
Sterile CDMO Market Expansion and Capacity Trends
April Stanley, MS MBA
Nice Insight
NI-8-26-MA42Sep 15, 2026
E. coli
Biomanufacturing with E. coli
April Stanley, MS MBA
Nice Insight
NI-8-26-MA9Sep 15, 2026
mRNA analytics
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA10Sep 15, 2026
invesment
The Funding Roller Coaster of 2023-2024
April Stanley, MS MBA
Nice Insight
NI-8-26-MA8Sep 15, 2026
Single-Use
The Changing Economics of Single-Use Biomanufacturing
Pharma's Almanac
PAO-09-26-PA-08Sep 10, 2026
CDMO Governance
The Governance Gap: Why Good CDMO Partnerships Still Fail
Pharma's Almanac
PAO-09-26-PA-07Sep 9, 2026
talent manufacturing
Pharma Layoffs and the Pharmaceutical Industry Outlook: Why Job Cuts Continue Despite Market Growth
April Stanley, MS MBA; David Alvaro, Ph.D.
Nice Insight
NI-9-26-MA53Sep 4, 2026
talent manufacturing
Global Talent Shortage
April Stanley, MS MBA; Koey Keylon
Nice Insight
NI-9-26-MA52Sep 4, 2026
Pathfinder
Conventional Peptide Synthesis vs. Recombinant Peptide Production: Which Manufacturing Strategy Is Better?
Nice Insight
PAO-26-PF-23Sep 4, 2026
Productivity
The Next Productivity Leap in Mammalian Cell Culture
Pharma's Almanac
PAO-09-26-PA-03Sep 3, 2026
Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02Sep 2, 2026
Capacity
Is the Bioreactor Arms Race Over?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-01Sep 1, 2026
MPS
What Will It Take for Organ-on-Chip Data to Replace Animal Studies?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-18Aug 31, 2026
mRNA / analytical
The mRNA Therapeutics Analytical Landscape
David Alvaro, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
NI-8-26-MA3Aug 28, 2026